Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOTUM | Q6P988 | 9/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 2/20 | 0.42 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | RORB | Q92753 | 1/20 | 0.42 |
| ▸ | COMT | P21964 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.40 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.40 |
| ▸ | GYS1 | P13807 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8842830 | 0.83 | KIF11 (0.47) | — | |
| SCHEMBL8842891 | 0.76 | PIN1 (0.47) | NOTUM | |
| SCHEMBL8842823 | 0.71 | RAB9A (0.50) | CYP1A2 | |
| SCHEMBL2698021 | 0.68 | NOTUM (0.61) | NOTUMCYP1A2KDRCOMTPDE3B | |
| SCHEMBL18955875 | 0.67 | MAPT (0.42) | NOTUMCYP1A2KDRKDM2BKDM4C | |
| SCHEMBL375961 | 0.66 | TSHR (0.59) | NOTUMKDRKDM2BKDM4C | |
| SCHEMBL322688 | 0.66 | KIF11 (0.59) | NOTUMCYP1A2KDRCOMT | |
| SCHEMBL27355471 | 0.66 | NOTUM (0.49) | NOTUMCYP1A2KDM2BKDM4CRORB | |
| SCHEMBL11622285 | 0.66 | KDR (0.68) | NOTUMCYP1A2KDRPDE3BPDE3A | |
| SCHEMBL15012259 | 0.66 | NOTUM (0.50) | NOTUMCYP1A2RORBCOMTPDE3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5674887-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| EP-0578477-B1 | Treatment of inflammatory bowel disease | LILLY CO ELI (US) | 1996-06-19 | — | — | EP | disclosed |
| US-5436258-A | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1995-07-25 | — | — | US | disclosed |
| EP-0587378-A1 | Prevention of bone resorption | ELI LILLY AND COMPANY (US) | 1994-03-16 | — | — | EP | disclosed |
| US-5294630-A | Treatment of inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0578477-A1 | Treatment of inflammatory bowel disease | ELI LILLY AND COMPANY (US) | 1994-01-12 | — | — | EP | disclosed |